SCHEMBL43437

SCHEMBL43437

O=C1NC(=O)c2ncccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 2/20 0.56
NSD2 O96028 2/20 0.56
PAX8 Q06710 2/20 0.56
ABL1 P00519 1/20 0.56
PLCG1 P19174 1/20 0.56
CES1 P23141 1/20 0.56
RIN1 Q13671 1/20 0.56
MEN1 O00255 1/20 0.56
THRB P10828 1/20 0.56
BLM P54132 1/20 0.56
KMT2A Q03164 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
GAA P10253 1/20 0.56
GSK3B P49841 1/20 0.52
CYP1A2 P05177 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CDC25B P30305 3/20 0.50
S100A4 P26447 3/20 0.50
PTPRC P08575 2/20 0.50
CTSL P07711 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30534404 1.00 TDP2 (0.56) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL13442892 0.88 TDP2 (0.63) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL2800822 0.82 TDP2 (0.50) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL12538393 0.78 TDP2 (0.50) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL3500581 0.73 ALDH1A1 (0.37) TDP2NSD2PAX8ABL1PLCG1
Phanquone SCHEMBL462025 0.72 MEN1 (1.00) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL5915065 0.72 TDP2 (0.81) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL460433 0.72 TDP2 (1.00) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL29551149 0.72 GAA (1.00) TDP2NSD2PAX8ABL1PLCG1
SCHEMBL29419580 0.72 TDP2 (1.00) TDP2NSD2PAX8ABL1PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1260 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122094660-A Composition in the form of an oil-in-water emulsion 2026-05-26 CN claimed
EP-4687829-A1 COMPOSITION FOR CARING FOR KERATIN MATERIALS L'OREAL (FR) 2026-02-11 EP claimed
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME OREAL (FR) 2025-12-18 US claimed
US-20250161201-A1 COSMETIC COMPOSITION THE BOOTS COMPANY PLC (GB) 2025-05-22 US claimed
WO-2025091220-A2 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
WO-2025091239-A1 COMPOSITION IN THE FORM OF OIL-IN-WATER EMULSION L'OREAL (FR) 2025-05-08 WO claimed
EP-4543408-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME L'OREAL (FR) 2025-04-30 EP claimed
CN-119654151-A Composition for caring skin 莱雅公司 2025-03-18 CN claimed
CN-119630382-A Solubilization of thiopyridone compounds and compositions containing same 莱雅公司 2025-03-14 CN claimed
EP-4479146-A1 COSMETIC COMPOSITION The Boots Company PLC (GB) 2024-12-25 EP claimed
EP-1042315-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS Klinge Pharma GmbH (DE) 2000-10-11 EP claimed
WO-1999031087-A1 CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS KLINGE PHARMA GMBH (DE) 1999-06-24 WO claimed
US-5849916-A Process for the preparation of 2,3-pyridinedicarboximides AMERICAN CYANAMID COMPANY (US) 1998-12-15 US claimed
EP-0663399-B1 Pyridine-2,3-dicarboxylic imides, process for their preparation and their use to control the growth of unwanted plants BASF AG (DE) 1998-06-10 EP claimed
EP-0661282-B1 Pyridine-2,3-dicarboxylic imides, process for their preparation and their use to control the growth of unwanted plants BASF AG (DE) 1998-04-22 EP claimed
EP-0812843-A2 Process for the preparation of 2,3-pyridinedicarboximides American Cyanamid Company (US) 1997-12-17 EP claimed
US-5679622-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1997-10-21 US claimed
US-5571774-A HERBICIDES BASF AKTIENGESELLSCHAFT (DE) 1996-11-05 US claimed
EP-0343108-B1 Resin compositions CIBA GEIGY AG (CH) 1994-08-31 EP claimed
US-4981888-A Resin compositions CIBA-GEIGY CORPORATION (US) 1991-01-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250161201-A1 COSMETIC COMPOSITION CYP19A1, SHBG, HSD17B11 TDP2 3897/4885NSD2 2140/4885PAX8 2697/4885
US-20250381116-A1 SOLUBILIZATION OF THIOPYRIDINONE COMPOUND AND COMPOSITION COMPRISING SAME TBCB, CCNB3, CYP24A1 TDP2 1001/4885NSD2 2271/4885PAX8 1791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.